Profile of mRNA Expression of IL-6 and IL-10 in Breast Cancer Patients with or Without Chemotherapy

摘要

Background: Breast cancer is a type of cancer that has a high prevalence, can occur in men and women. Cytokines are factors that are known to have good properties of tumor growth and tumor inhibitory effects. Cytokine has an important role in the control of the immune system. Development of breast carcinoma is closely related to mRNA expression of IL-6 as pro-inflammatory cytokine and mRNA expression of IL-10 as anti-inflammatory cytokine. Purpose: Examine changes in mRNA expression of proinflammatory cytokine and anti-inflammatory cytokine in breast cancer patients with or without chemotherapy. Method: This is a case-control study, 12 subjects with breast cancer with chemotherapy as case group and 12 subjects with breast cancer without chemotherapy as control group. In this study we using PCR and RFLP techniques to detect polymorphisms in IL-6 and IL-10 gene. Results: In RFLP analysis, found that IL-6 and IL-10 gene were not polymorphic in all subjects for both case and control groups. Mean value of IL-6 mRNA on breast cancer patients without receiving chemotheraphy was 10.84±0.48 whereas on breast cancer patients with chemotherapy was 6.28±1.19. Mean value of IL-10 mRNA on breast cancer patients without receiving chemotheraphy was 6.76±0.81 whereas on breast cancer patients with chemotherapy was 9.81±1.07. The mean value of IL-6 mRNA on breast cancer patients without receiving chemotheraphy was statistically significant higher than in patients with chemotheraphy. In contrast, mean value of IL-10 mRNA on breast cancer patients without receiving chemotheraphy was statistically significant lower than in patients with chemotherapy. Conclusion: Combination of chemotherapy docetaxel, adriamycin, cyclophosphamide cause a decrease in mRNA expression of IL-6 and an increase in the expression of mRNA of IL-10 in patients with breast cancer.